Videos

"I think there have been a lot of what I would consider incremental improvements over the past few years," Smita De, MD, PhD.

“The use of perioperative subcutaneous heparin should be considered in all patients that are undergoing IPP surgery,” says Thairo Pereira, MD.

“We have definitely seen significant trends toward transparency in hospital pricing, and in regulations designed to promote that, as well as PBM reform,” says Mara R. Holton, MD.

"In general, I think there's a tremendous amount of variability in terms of how sexual medicine specialists treat patients who have had intimacy issues relating to robotic prostatectomy," says Stanton Honig, MD.

"We as a specialty have to do a better job of educating our colleagues and referring docs," says Roger R. Dmochowski, MD, MMHC, FACS

"This year, we saw a decrease of a couple percent for physician reimbursement to levels that were even lower than pre-COVID times," says Edward Karpman, MD, FACS.

"What we found is, in a retrospective review of nearly 500 patients over a 3-year span, none of those patients reported erectile dysfunction, none of them reported loss of penile sensation, and none of them required a trip to the operating room for intervention," says Amy Pearlman, MD.

"I think that overall, one should do what one is comfortable with, within the scope of your practice and your resources," says Smita De, MD, PhD.

Dr Daniel Allan Hamstra highlights ongoing and planned trials investigating rectal spacers in patients with prostate cancer undergoing radiation therapy that he hopes will provide more data on toxicity reduction and preservation of sexual function.

Dr Hamstra recommends rectal spacers in certain prostate cancer patients to reduce rectal toxicity, allow dose escalation, and preserve sexual function, but advises judicious use due to potential complications and lack of long-term quality of life data with newer spacers.

"You can really gain so much insight from other people who have done what you're looking to do," says Helen L. Bernie, DO, MPH.

"So far, we have only 2 published, which is the cardiovascular results, which showed no increase in cardiovascular events, and the sexual function results, showing improvements in libido, but not erectile function, in up to 2 years," says Mohit Khera, MD, MBA, MPH.

“How we set up patients for success comes not just in our individual clinical encounters, but also how we approach patient care as an organization,” says Niels V. Johnsen, MD, MPH.

"We've seen that the rate of burnout among women in urology is rising particularly quickly," says Marah C. Hehemann, MD.

“One of our early findings showed that males who have IPPs use less depression medication, have less emergency room visits, and have less clinic visits for psychiatry-related conditions,” says Roei Golan.

“I do think that we have been leveraging opportunities like conferences to have meaningful discussions about these topics and see where we are and how we can get better,” says Denise Asafu-Adjei, MD, MPH.

"[It’s about] understanding that as urologists, we are board certified to take care of all genders, and we do have data and evidence to support us in taking better care of our female patients," says Rachel Rubin, MD.

“Then finally, when we asked about Xiaflex, it was only two-thirds of programs, less than 70% of programs listed that they were having the residents exposed to Xiaflex,” says Justin Loloi, MD.

"We found that the prevalence of both depression and anxiety were significantly higher in the men's health clinic," says Nestor F. Suria Cordero, MD.

"This is a phase 1 clinical trial, so we're primarily looking at safety and adverse events. We’ve had none in the 46 participants that we have so far," says David Alejandro Velasquez.

"It's really great because that means we can look at treating men sooner even if they're still presenting, and in what we would traditionally or classically call the acute phase, we're able to offer an FDA approved therapy at an earlier timeline," says Jesse N. Mills, MD.

“This year in particular, we really attempted to highlight a novel conversation about financial toxicity,” says Mara R. Holton, MD.

Drs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.

"[The findings] certainly made me a lot less anxious for those patients who do need to continue their aspirin," says Smita De, MD, PhD.

"I think the main take-home message from our study is that this is a really powerful prognostic prediction tool," says Charles Parker, MD.

“I think the takeaway from the active surveillance [session] is that we've increased the utilization of active surveillance for low-risk appropriate men,” says David S. Morris, MD, FACS.

Analysis of SpaceOAR trial and pooled data found reduced penile bulb radiation dose correlated with better preservation of sexual function over long-term follow-up, suggesting rectal spacers help maintain erectile function in some men with prostate cancer undergoing radiation therapy.

The Phase 3 trials for the Barrigel and BioProtect rectal spacers demonstrated a dosimetric advantage and reduced rectal toxicity similar to SpaceOAR, but data on long-term toxicity and patient-reported outcomes is still needed to fully evaluate the newer spacers.

"The providers–the nurses and the physicians and the extenders–are checking out and burning out, which is affecting quality and delivery. To me, it's a national health care crisis," says Scott A. MacDiarmid, MD, FRCPSC.